Literature DB >> 22645304

Evidence for DNA-binding domain--ligand-binding domain communications in the androgen receptor.

Christine Helsen1, Vanessa Dubois, Annelien Verfaillie, Jacques Young, Mieke Trekels, Renée Vancraenenbroeck, Marc De Maeyer, Frank Claessens.   

Abstract

DNA binding as well as ligand binding by nuclear receptors has been studied extensively. Both binding functions are attributed to isolated domains of which the structure is known. The crystal structure of a complete receptor in complex with its ligand and DNA-response element, however, has been solved only for the peroxisome proliferator-activated receptor γ (PPARγ)-retinoid X receptor α (RXRα) heterodimer. This structure provided the first indication of direct interactions between the DNA-binding domain (DBD) and ligand-binding domain (LBD). In this study, we investigated whether there is a similar interface between the DNA- and ligand-binding domains for the androgen receptor (AR). Despite the structural differences between the AR- and PPARγ-LBD, a combination of in silico modeling and docking pointed out a putative interface between AR-DBD and AR-LBD. The surfaces were subjected to a point mutation analysis, which was inspired by known AR mutations described in androgen insensitivity syndromes and prostate cancer. Surprisingly, AR-LBD mutations D695N, R710A, F754S, and P766A induced a decrease in DNA binding but left ligand binding unaffected, while the DBD-residing mutations K590A, K592A, and E621A lowered the ligand-binding but not the DNA-binding affinity. We therefore propose that these residues are involved in allosteric communications between the AR-DBD and AR-LBD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22645304      PMCID: PMC3434514          DOI: 10.1128/MCB.00151-12

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  59 in total

1.  Inherited and de novo androgen receptor gene mutations: investigation of single-case families.

Authors:  O Hiort; G H Sinnecker; P M Holterhus; E M Nitsche; K Kruse
Journal:  J Pediatr       Date:  1998-06       Impact factor: 4.406

2.  The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions.

Authors:  Fred Schaufele; Xavier Carbonell; Martin Guerbadot; Sabine Borngraeber; Mark S Chapman; Aye Aye K Ma; Jeffrey N Miner; Marc I Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-01       Impact factor: 11.205

3.  Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains.

Authors:  D M Tanenbaum; Y Wang; S P Williams; P B Sigler
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

4.  Male infertility and androgen receptor gene mutations: clinical features and identification of seven novel mutations.

Authors:  Alberto Ferlin; Cinzia Vinanzi; Andrea Garolla; Riccardo Selice; Daniela Zuccarello; Carla Cazzadore; Carlo Foresta
Journal:  Clin Endocrinol (Oxf)       Date:  2006-11       Impact factor: 3.478

5.  Residual activity of mutant androgen receptors explains wolffian duct development in the complete androgen insensitivity syndrome.

Authors:  Sabine E Hannema; Ian S Scott; John Hodapp; Howard Martin; Nick Coleman; John W Schwabe; Ieuan A Hughes
Journal:  J Clin Endocrinol Metab       Date:  2004-11       Impact factor: 5.958

6.  Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor.

Authors:  E Kalkhoven; J E Valentine; D M Heery; M G Parker
Journal:  EMBO J       Date:  1998-01-02       Impact factor: 11.598

7.  Discordant measures of androgen-binding kinetics in two mutant androgen receptors causing mild or partial androgen insensitivity, respectively.

Authors:  D L Shkolny; L K Beitel; J Ginsberg; G Pekeles; L Arbour; L Pinsky; M A Trifiro
Journal:  J Clin Endocrinol Metab       Date:  1999-02       Impact factor: 5.958

8.  The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.

Authors:  A K Shiau; D Barstad; P M Loria; L Cheng; P J Kushner; D A Agard; G L Greene
Journal:  Cell       Date:  1998-12-23       Impact factor: 41.582

9.  Azoospermia associated with a mutation in the ligand-binding domain of an androgen receptor displaying normal ligand binding, but defective trans-activation.

Authors:  Q Wang; F J Ghadessy; A Trounson; D de Kretser; R McLachlan; S C Ng; E L Yong
Journal:  J Clin Endocrinol Metab       Date:  1998-12       Impact factor: 5.958

10.  Human androgen receptor gene ligand-binding-domain mutations leading to disrupted interaction between the N- and C-terminal domains.

Authors:  J Jääskeläinen; A Deeb; J W Schwabe; N P Mongan; H Martin; I A Hughes
Journal:  J Mol Endocrinol       Date:  2006-04       Impact factor: 5.098

View more
  25 in total

Review 1.  Allosteric pathways in nuclear receptors - Potential targets for drug design.

Authors:  Elias J Fernandez
Journal:  Pharmacol Ther       Date:  2017-10-31       Impact factor: 12.310

2.  A naturally occurring insertion of a single amino acid rewires transcriptional regulation by glucocorticoid receptor isoforms.

Authors:  Morgane Thomas-Chollier; Lisa C Watson; Samantha B Cooper; Miles A Pufall; Jennifer S Liu; Katja Borzym; Martin Vingron; Keith R Yamamoto; Sebastiaan H Meijsing
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-14       Impact factor: 11.205

3.  Nuclear receptor full-length architectures: confronting myth and illusion with high resolution.

Authors:  Fraydoon Rastinejad; Vincent Ollendorff; Igor Polikarpov
Journal:  Trends Biochem Sci       Date:  2014-11-28       Impact factor: 13.807

4.  Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer.

Authors:  Zhong Chen; Xun Lan; Jennifer M Thomas-Ahner; Dayong Wu; Xiangtao Liu; Zhenqing Ye; Liguo Wang; Benjamin Sunkel; Cassandra Grenade; Junsheng Chen; Debra L Zynger; Pearlly S Yan; Jiaoti Huang; Kenneth P Nephew; Tim H-M Huang; Shili Lin; Steven K Clinton; Wei Li; Victor X Jin; Qianben Wang
Journal:  EMBO J       Date:  2014-12-22       Impact factor: 11.598

5.  The androgen receptor depends on ligand-binding domain dimerization for transcriptional activation.

Authors:  Christine Helsen; Frank Claessens; Sarah El Kharraz; Vanessa Dubois; Martin E van Royen; Adriaan B Houtsmuller; Ekatarina Pavlova; Nina Atanassova; Tien Nguyen; Arnout Voet; Roy Eerlings; Florian Handle; Stefan Prekovic; Elien Smeets; Lisa Moris; Wout Devlies; Claes Ohlsson; Matti Poutanen; Kevin J Verstrepen; Geert Carmeliet; Kaisa-Mari Launonen; Laura Helminen; Jorma J Palvimo; Claude Libert; Dirk Vanderschueren
Journal:  EMBO Rep       Date:  2021-10-18       Impact factor: 8.807

Review 6.  Understanding nuclear receptor form and function using structural biology.

Authors:  Fraydoon Rastinejad; Pengxiang Huang; Vikas Chandra; Sepideh Khorasanizadeh
Journal:  J Mol Endocrinol       Date:  2013-11-07       Impact factor: 5.098

7.  Androgen induces a switch from cytoplasmic retention to nuclear import of the androgen receptor.

Authors:  Li Ni; Ryan Llewellyn; Cristina T Kesler; Joshua B Kelley; Adam Spencer; Chelsi J Snow; Leonard Shank; Bryce M Paschal
Journal:  Mol Cell Biol       Date:  2013-10-07       Impact factor: 4.272

8.  The transcription intermediary factor 1β coactivates the androgen receptor.

Authors:  N Van Tilborgh; L Spans; C Helsen; L Clinckemalie; V Dubois; E Lerut; S Boonen; D Vanderschueren; F Claessens
Journal:  J Endocrinol Invest       Date:  2013-04-08       Impact factor: 4.256

9.  Hydrogen sulfide represses androgen receptor transactivation by targeting at the second zinc finger module.

Authors:  Kexin Zhao; Shuangshuang Li; Lingyun Wu; Christopher Lai; Guangdong Yang
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

10.  Emerging mechanisms of enzalutamide resistance in prostate cancer.

Authors:  Frank Claessens; Christine Helsen; Stefan Prekovic; Thomas Van den Broeck; Lien Spans; Hendrik Van Poppel; Steven Joniau
Journal:  Nat Rev Urol       Date:  2014-09-16       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.